leisure time -WSS

leisure time

author：hotspot 2025-10-01 21:40:06 - browse：15246

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.

In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.

Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： UnitedHealth argues against case alleging wrongful AI care denials

WSS

Listen: More tumult at BIO & coercive care for sickle cell patients

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Biogen joins immunology wave with $1.15 billion acquisition of HI

Addressing health care workers' trauma can help fight burnout

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Citing H5N1 threat, CDC urges peak flu monitoring this summer

focus

leisure time

Wikipedia

Psychedelics group wrestles with new pharma identity

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

Medical records are filled with copy

Oak Street deal isn't the answer to health care's woes

Activists slam private health insurers over coverage restrictions

What a koala virus tells us about the human genome

BioMarin wins approval for gene therapy to treat hemophilia A

Listen: More tumult at BIO & coercive care for sickle cell patients

The high cost of giving birth even with insurance

Digital health: a case of mistaken identity

leisure time

HHS suspends federal funding for EcoHealth Alliance

Questions and answers about ramping up H5N1 bird flu vaccine

CVS is willing to dump 10% of its Medicare Advantage members

For longer

Boston hospital trains restaurant workers on naloxone for overdoses

Scrutiny of post

explore

hotspot

hotspot

knowledge